MEOPA
ApprovedSmall molecule
MEOPA is one of 86 small molecule programs targeting Sedation. It is currently in Approved.
3
Indications
6
Total Trials
1
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
138 competitors in Dementia
#DrugCompanyPhaseTrials
1Leqembi
EisaiPhase 3
Depacon
AbbViePhase 3
Abilify
OtsukaPhase 3
Glucophage
EMD SeronoPhase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Aricept
EisaiPhase 3
Seroquel
AstraZenecaPhase 3
Dayvigo
EisaiPhase 2
MEOPA
AAssistance Publique - Hôpitaux de Paris
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nitrous Oxide1 trial
Renal Colic1 trial
Elderly1 trial
Contribution of the MEOPA in the Physiotherapy Care of Painful Articular Steepness Among Elderly
Unknown status·—·Phase 4·NCT02230007·64 enrolled
1 more indication
Dementia1 trial
Use of MEOPA (Equimolar Mixture of Nitrogen Protoxide and Oxygen) for Elderly With Dementia
Completed·—·N/A·NCT00822224·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MEOPA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details